|Bid||30.22 x 800|
|Ask||30.30 x 800|
|Day's Range||27.95 - 31.09|
|52 Week Range||11.54 - 36.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||33.44|
Moderna (MRNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
A number of biotech and pharmaceutical stocks have rallied sharply on hopes they can be part of the response to the coronavirus pandemic. Nano-cap AIM ImmunoTech (NYSEAMERICAN:AIM) stock has been one of them. In recent weeks, AIM stock has pulled back after a parabolic rally.Source: Shutterstock Beginning Feb. 26, shares rose nearly 500% in just nine sessions. They've since retreated -- but still have gained 75% over the last month.AIM ImmunoTech itself has stoked those hopes by highlighting its potential ability to treat the coronavirus and/or provide a vaccine. But as always in the biotech space, the keyword is "potential."InvestorPlace - Stock Market News, Stock Advice & Trading TipsAfter all, AIM ImmunoTech is one of literally dozens of companies racing to respond to the coronavirus. Any investor buying the stock at this point, even after the pullback, has to believe the company has some kind of edge over those rivals. But the history of the company strongly suggests that is unlikely. The Rally in AIM StockIt does look like some savvy and/or intrepid investors figured out somewhat early that AIM stock could benefit from pandemic fears. Shares traded as low as 38 cents last year, after a long decline capped by an $8 million equity offering in late September. But at the beginning of 2020, the stock rallied toward roughly $1. * 10 Stocks to Buy That Will Benefit From Coronavirus Mayhem In February, AIM started inserting itself into the coronavirus discussion. On Feb. 11, the company announced it had filed patent applications for the use of its drug candidate Ampligen. The applications covered usage as a therapy; Ampligen's potential role in a vaccine; and a "high-volume manufacturing process" for the drug.That set off a brief rally that quickly reversed. An update a week later from AIM's chief executive officer highlighting Ampligen's promise was mostly ignored by the market.But the company finally got investor attention on Feb. 27, when it announced an effort to get Ampligen into China as a prophylactic for the coronavirus. Shares then nearly tripled in a single session when AIM disclosed a trial with Japan's National Institute of Infectious Diseases.That day, AIM closed above $6. It's since declined by nearly 70%. The Bull CaseTo be fair, AIM has highlighted some evidence that Ampligen could be effective in treating the coronavirus. As the CEO noted last month, Ampligen offered "significant efficacy" against the SARS (severe acute respiratory syndrome) virus in a study using mice.SARS and the coronavirus are similar. In fact, the World Health Organization has designated the official name of the virus (as opposed to the disease) SARS-CoV-2. The '2' in the name refers to the fact that, as the agency put it, the two viruses are "genetically related."Meanwhile, in other trials targeting conditions ranging from cancer to chronic fatigue syndrome, Ampligen's safety appears well-documented.So it at least appears possible that Ampligen could have some success in combating the coronavirus. And its safety profile means that testing by agencies could move ahead relatively promptly. Why AIM ImmunoTech?But there are some significant holes in the bull case.The most notable is the fact that competition is larger and likely faster. There are giants and innovators leading the way in coronavirus treatments and vaccines. Gilead Sciences' (NASDAQ:GILD) remdesivir shows promise as a treatment. Moderna (NASDAQ:MRNA), whose "messenger RNA" technology underpinned what was at the time the largest biotech initial public offering ever, is working toward a vaccine.Inovio (NASDAQ:INO) stock has rallied on similar hopes. So has Novavax (NASDAQ:NVAX), and many others.The idea that AIM will win seems optimistic, to say the least. And it's worth noting that after a barrage of press releases, the company has been quiet since the Japan announcement on March 9. The following day, the company filed an updated prospectus allowing for the sale of $18 million in stock in a so-called "at the market" offering.Relative to MRNA stock, I've written that investors shouldn't be chasing coronavirus stocks in general. If they insist on doing so, they should at least focus on those companies with a decent chance of winning. AIM doesn't look like one of those stocks. A Tortured HistoryIt's even more difficult to believe that AIM ImmunoTech can win given its long and disappointing history. This is a company, then known as Hemispherx Biopharma, that went public in 1996. Then, too, Ampligen was its flagship product.24 years later, little has changed. Ampligen still is the core product, as sales of interferon Alferon N Injection have faded toward or to zero. Ampligen is being studied in several clinical trials -- but all are either Phase 1 or Phase 2.This is a company that's been public for almost a quarter of a century -- and made basically zero progress. Even with this bounce, the stock is down 75% over the past year and 91% over the last three. Losses over longer holding periods exceed 99%.Cash burn is an issue. Research and development spending was just $3.3 million through the first nine months of 2019. Gilead spent $7.2 billion over the same period.An investor betting on AIM stock -- which, again, has gained 75% over the last month -- has to believe Ampligen has at least a chance of garnering material revenue as either a coronavirus treatment or as part of a vaccine.And that, in turn, means that a company that has moved at a glacial pace for 24 years will suddenly kick into gear. It means that AIM, backed by barely $1 million in R&D spend each quarter, is going to outsmart and outwork giants with significantly larger resources. It means that Ampligen, which hasn't really worked to treat anything, will be the cure for a global pandemic.In theory, it's possible that bet pays off. In practice, it's awfully difficult to see how.Vince Martin has covered the financial industry for close to a decade for InvestorPlace.com and other outlets. He has no positions in any securities mentioned. More From InvestorPlace * America's Richest ZIP Code Holds Wealth Gap Secret * 10 Stocks to Buy That Will Benefit From Coronavirus Mayhem * 5 Bank Stocks to Buy Now Because This Isn't 2008 Again * 12 Stocks to Buy That Are Already Positive The post In the Coronavirus Vaccine Race, AIM Stock Isn't a Likely Winner appeared first on InvestorPlace.
The trials of a drug by Gilead Sciences are some of the most advanced work being done on potential COVID-19 vaccines and treatments, one of the few disease-specific options patient-filled hospitals have.
A mix of legacy drugmakers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel coronavirus.
Coronavirus fears have triggered volatility, a correction and ultimately a bear market in U.S. stocks in 2020. Many companies have suffered massive price drops, but a handful of stock picks have seen their prices hold up - and in some cases even soar. One such cluster includes pharmaceutical companies and other health-care stocks that are in the race to develop COVID-19 coronavirus vaccines and therapeutics.You can't overstate the stakes. As of March 11, there were 129,771 officially recorded coronavirus cases worldwide, causing more than 4,700 deaths, across 125 countries. The World Health Organization (WHO) has officially declared this a pandemic, and the threat to life is very real. That has governments increasingly shutting down any mass gatherings of people to slow the spread.The hope? That they can buy time for pharmaceutical companies to come up with antivirals and vaccines.More than 30 Big Pharma and small biotechnology companies alike are already involved in COVID-19 coronavirus treatment and vaccine development. But other health-care stocks are rising to the challenge, too: Makers of diagnostic test kits, sanitizers and protective masks are all ramping up to meet unprecedented demand.Here are 10 health and pharmaceutical companies playing a role in the fight to control the COVID-19 coronavirus. Each of these stocks has the potential for considerable gain, whether it's because they're developing a treatment or their products are in greater need amid the outbreak. And to date, each stock has outperformed the S&P; 500 since it started plunging in mid-February, with many posting considerable gains. SEE ALSO: 11 Defensive Dividend Stocks for Riding Out the Storm
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.
Vir Biotechnology Inc. teamed with WuXi Biologics and Biogen Inc. to rush a potential treatment for COVID-19 patients into clinical trials, possibly as soon as June. San Francisco-based Vir (NASDAQ: VIR) said early Wednesday that its potential antibody treatment for the coronavirus that causes COVID has been transferred "several weeks ago" to China-based WuXi and Biogen (NASDAQ: BIIB) and could be tested in humans within three to five months. Vir's candidate is the latest potential treatment or vaccine rushed into service to defeat COVID.
A saying on Wall Street is that the market hates uncertainty, and unfortunately that looks to be playing out in global stock markets currently. In historically quick fashion, the vast majority of stocks are hitting bottom – most have already hit 52-week lows and many are hitting multi-year lows. It’s a different story with certain food and healthcare-related stocks. A screen of TipRanks for stocks holding up in this tough environment details a few names that hit their 52-week highs. Not coincidentally, they are all involved with fighting the novel coronavirus, or Covid-19Rightfully so, Covid-19 fears continue to spook a very high number of citizens across the globe and economic conditions are grinding, at least temporarily, to a halt. Without some clarity on which companies can withstand, and even survive this economic hit, one bona fide certainty right now is the companies directly involved in the fight against this novel virus could benefit investors and humanity in big ways.Below are overviews of three healthcare stocks front and center in the fight against covid-19. Using the TipRanks database and screener details that these stocks stand out for their positive ratings and compelling mix of upside potential and downside protection, due primarily to the fact they are working overtime to find solutions to covid-19’s unprecedented spread. Let's take a closer look.Regeneron (REGN)Biopharmaceutical company Regeneron hit its 52-week highs last week. The firm is on the hunt for finding either a vaccine for Covid-19 or drug candidates that help reduce the severity of lung complications and fevers for patients that are susceptible to the virus’s key challenges. This is of course appealing for its potential to help stop the virus in its tracks. For investor portfolios, it offers a very compelling mix of upside potential and a stock that is unlikely to plummet in the near term.According to research firm Canaccord analyst John Newman, drug Kevzara could hold “meaningful upside for REGN and the U.S. economy.” In fact, any global citizen could benefit as clinical trials (Phase II and III) move quickly forward because it is thought to reduce “levels of IL-6” that are found in the virus and can increase mortality, especially from patients already suffering from pneumonia.The company is also working feverishly to “develop a two-antibody cocktail against Covid-19.” Trials could start this summer where “success here could carry meaningful upside for patients and the entire US (and world) economy.Newman projects 2020 sales of $8.8 billion for year-over-year growth above 12%. The analyst expects EPS of $27.48 for only modest annual projected growth of 11.4%. The valuation is quite reasonable – the forward P/E is currently only at about 14.Newman rates Regeneron shares a Buy along with a $550 price target, which represents upside of 21% from the current share price of $430. (To watch Newman's track record, click here)Overall, Regeneron has had 9 bullish analysts in its corner over the last three months, and 6 analysts playing it safe on the sidelines. That said, the 12-month average price target of $465 showcases a modest upside of 3% from current levels. (See Regeneron stock analysis on TipRanks)Moderna (MRNA)To further illustrate the protection that these leading stocks that are fighting the coronavirus can provide for your portfolio, clinical-stage biotech Moderna is up 28% year-to-date. Moderna specializes in providing therapies and vaccines based off messenger RNA delivery methods.Research firm Piper Sandler provided some insight into Moderna’s approach to developing a vaccine against the novel coronavirus. Moderna has been collaborating directly with the National Institutes of Health (NIH), and analyst Edward Tenthoff marveled at the speed with which Moderna was able to sequence data shared January 11 by Chinese authorities following the initial outbreak in China. According to Tenthoff and his team, “this unprecedented accomplishment in vaccine development highlights the speed of Moderna’s mRNA vaccine discovery and manufacturing process.” Data from the Phase I study could be available as soon as summer and a larger study could happen this fall into early 2021.No profits are projected for Moderna for at least the next three years, but sales could jump 38% this year to $83.1 million and reach $100 million for all of 2021.Tenthoff's reiterates an Overweight rating on MRNA along with a $34 price target -- 40% upside from the current share price.The word of the Street is an overwhelmingly bullish one for this coronavirus stock, as TipRanks analytics exhibit MRNA as a Strong Buy. Out of 15 analysts polled by TipRanks in the last 3 months, 6 are bullish on Moderna stock. With a return potential of 26%, the stock’s consensus target price stands at $31.67. (See Moderna stock analysis on TipRanks)Gilead (GILD)Biopharma giant Gilead hit a 52-week high last week and is known best for its Solvadi drug that cures patients afflicted with Hepatitis C. Its drug candidate remdesivir has received international attention, due in good part to President Donald Trump suggesting its efficacy (effectiveness) in treating complications arising from Covid-19.Despite this promise, the results appear to be only preliminary and not conclusively tested via the drug candidate development process. However, on Friday, Piper Sandler analyst Tyler Van Buren upgraded his rating on Gilead from Neutral to Overweight and bumped up his price target to $90 per share, a significant upgrade from an earlier target of $70. (To watch Van Buren's track record, click here)Van Buren commented: “Following our call with Gilead's CMO, Merdad Parsey, MD, PhD, and the learnings over the past 48 hours..we are upgrading GILD shares to Overweight as we believe remdesivir will be approved by the FDA very soon, which should lead to continued outperformance. Many important takeaways from the call are highlighted below, but if the data are positive, there will be tremendous pressure to approve the COVID-19 drug within days.”The sees a “multi-billion dollar global opportunity” from the approval of remdesivir that could represent a significant boost to Gilead’s projected 2020 full year sales of $22.4 billion. This would be a bright spot for Gilead which, after the hugely successful launch of Solvadi a few years ago, has struggled to grow its total sales. Remdesivir is also in Phase III trials in China and the forthcoming results could be quite soon.All in all, Wall Street almost evenly split between the bulls and those choosing to play it safe. Based on 19 analysts tracked in the last 3 months, 10 rate GILD a Buy, 8 say Hold, while 1 issues a Sell. The 12-month average price target stands at $77.67, marking a modest 4.5% upside for the stock. (See Gilead stock analysis on TipRanks)
There are some hard limits to the vaccine development process that mean we are not going to see any preventative immune therapies to fight the new coronavirus for at least a year to 18 months. The company will look at possibly doing so under an emergency use authorization from the Food and Drug Administration, which is similar to how certain testing procedures are being granted approval for use now, bypassing the typical process under which such diagnostic tools are given the go-ahead. Moderna's solution, which was developed in partnership with the National Institute of Allergy and Infectious Diseases, is already the fastest potential vaccine to enter the human clinical trial phase.
CEO Stéphane Bancel also said the company was scaling up its manufacturing capacity so it will be able to make millions of doses of the vaccine a month.
Moderna said its coronavirus vaccine candidate may be available to emergency workers by fall, with wider provision in 12 to 18 months.
In the latest trading session, Moderna (MRNA) closed at $28.14, marking a -0.46% move from the previous day.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
The FDA approves Gilead's (GILD) sNDA for Epclusa to treat chronic hepatitis C infection in children aged six years and above or weighing at least 17 kg.
Emergent BioSolutions (EBS) teams up with Vaxart to support development of the latter's oral vaccine candidate for treating coronavirus disease.
The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals
Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.
As COVID-19 case counts and deaths continue to rise and the stock market has struggled to regain its footing, one bright spot are the drugmakers and diagnostics companies moving forward with plans to develop tests, treatments, and vaccines for the novel coronavirus.